Advance Online
A lady with curly brown hair smiling outside.

FDA Approves Wynzora® Cream for Plaque Psoriasis

A new topical treatment option is now available to patients.

Plaque psoriasis is the most common type of psoriasis, with approximately 80 percent to 90 percent of patients with psoriasis developing plaques.[1] On July 22, 2020, the U.S. Food and Drug Administration approved Wynzora® cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) for the treatment of plaque psoriasis in adult patients.

Wynzora® cream marks the first cream formulation of a vitamin D based treatment (calcipotriene) and a corticosteroid (betamethasone dipropionate). Using proprietary PAD™ Technology, researchers developed a way to enable stability of both treatments in a cream formulation that is meant to be convenient for patients to use.

Data from phase 3 trials of Wynzora® cream showed it to have statistically significant treatment efficacy as well as favorable patient-reported outcomes, compared to another calcipotriene and betamethasone dipropionate topical treatment.

Manufacturer, MC2 Therapeutics, is also investigating drug candidates for other indications such as atopic dermatitis.

[1] https://www.aad.org/public/diseases/psoriasis/what/overview

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.